Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the environmental exposure unit

Allergy and Asthma Proceedings

Volumn 29, Issue 3, 2008, Pages 304-312

  Day, James H ^a,b   Briscoe, Maureen P ^a   Ratz, Jodan D ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Allergic rhinitis; Antihistamine; EEU; Efficacy; Environmental exposure unit; Leukotriene receptor antagonist; Levocetirizine; Montelukast; Pollen; Ragweed

Indexed keywords

ACETIC ACID DERIVATIVE; CETIRIZINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; MONTELUKAST; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HAY FEVER; HUMAN; MALE; MICROCLIMATE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RAGWEED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACETATES; ADULT; AMBROSIA; CETIRIZINE; ENVIRONMENT, CONTROLLED; ENVIRONMENTAL EXPOSURE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 46649083384     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3109     Document Type: Article

References (14)

1. Settipane RA, and Charnock DR. Epidemiology of rhinitis: Allergic and nonallergic. Clin Allergy Immunol 19:23-34, 2007.
2. Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol 90:7-12, 2003.
3. Simons FE. Advances in H1-antihistamines. N Engl J Med 351: 2203-2217, 2004.
4. Morgan MM, Khan DA, and Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: Focus on oral antihistamines. Ann Pharmacother 39:2056-2064, 2005.
5. Day JH, and Briscoe MP. Environmental exposure unit: A system to test anti-allergic treatment. Ann Allergy Asthma Immunol 83:83-89, 1999.
6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Allergic rhinitis: Clinical development programs for drug products. Draft Guidance for Industry, April 2000. U.S. Department of Health and Human Services, Washington, D.C.
7. Day JH, Briscoe MP, Rafeiro E, and Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 58:109-118, 2004.
8. Day JH, Ellis AK, Rafeiro E, et al. Experimental models for the evaluation of treatment of allergic rhinitis. Ann Allergy Asthma Immunol 96:263-277, 2006.
9. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, and Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 97:664-671, 2006.
10. Grainger J, and Drake-Lee A. Montelukast in allergic rhinitis: A systematic review and meta-analysis. Clin Otolaryngol 31:360-367, 2006.
11. Rodrigo GJ, and Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: A systematic review of randomized trials. Ann Allergy Asthma Immunol 96:779-786, 2006.
12. Weinstein SF, Philip G, Hampel FC, et al. Onset of efficacy of montelukast in seasonal allergic rhinitis. Allergy Asthma Proc 26:41-46, 2005.
13. Bachert C, Bousquet J, Canonica GW, et al. and XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 114:838-844, 2004.
14. Bousquet J, Demarteau N, Mullol J, et al. and XPERT study group. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 60:788-794, 2005.